Table 1.

Effects of elacridar in the cell cycle of imatinib-sensitive and imatinib-resistant cells.

		G0/G1 (%)	S (%)	G2/M (%)
K562 Cells
	Control	39.7 ± 0.7	49.0 ± 0.6	11.8 ± 0.9
	Elacridar 0.25 μM	37.0 ± 1.4	51.3 ± 0.7	11.7 ± 1.7
	Elacridar 10 μM	41.2 ± 1.6	41.8 ± 1.6 **	17.0 ± 1.8
	IMA 100 ηM	38.3 ± 2.1	47.3 ± 0.8	14.3 ± 1.7
	Elacridar 0.25 μM + IMA 100 ηM	46.2 ± 2.7 $	41.3 ± 2.4 **,$	12.5 ± 2.3
K562-RC Cells
	Control	67.3 ± 2.2	22.5 ± 1.4	10.2 ± 0.8
	Elacridar 0.25 μM	65.2 ± 3.2	23.8 ± 2.2	11.0 ± 1.0
	Elacridar 10 μM	62.5 ± 3.4	23.5 ± 1.6	14.0 ± 1.9
	IMA 100 ηM	51.8 ± 2.2 **	38.2 ± 0.9 ***	10.0 ± 1.3
	Elacridar 0.25 μM + IMA 100 ηM	52.7 ± 1.9 **	37.5 ± 1.4 ***	9.8 ± 0.8
K562-RD Cells
	Control	63.2 ± 1.2	26.8 ± 1.1	10.2 ± 0.3
	Elacridar 0.25 μM	60.0 ± 2.3	29.0 ± 2.1	11.0 ± 0.4
	Elacridar 10 μM	63.8 ± 2.4	23.3 ± 2.1	13.0 ± 0.4
	IMA 100 ηM	51.3 ± 2.1 ***	37.8 ± 1.9 ***	10.8 ± 0.4
	Elacridar 0.25 μM + IMA 100 ηM	54.5 ± 1.7 *	32.7 ± 1.2	12.8 ± 1.2

* p < 0.05, ** p < 0.01, *** p < 0.001 comparing with control; ^$ p < 0.05, comparing with lower dose of correspondent inhibitor. IMA: imatinib.